Cervical dysplasia: Assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy

Lim, Elaine; Ng, Shi Len; Li, Jialiang; Chang, Alexander R.; Ng, Joseph; Ilancheran, A.; Low, Jeffrey; Quek, Swee Chong; Tay, Eng Hseon

doi:10.1016/j.ygyno.2010.07.028

Cited by 42 publications

(31 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…they were associated with other type of malignancies and/or morbidities, such as oral squamous cell carcinoma, head and neck cancer, ovarian cancer and primary hyperthyroidism). Moreover, three studies were excluded due to study design inconsistencies that did not allow calculation of PAX1 methylation status per CIN stage [19,22,25]. The baseline characteristics of included studies, corresponding to a total population of 1385 individuals, are presented in Table 1 [23,24,26,[31][32][33][34].…”

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

See 1 more Smart Citation

PAX1 methylation as an auxiliary biomarker for cervical cancer screening: A meta-analysis

Nikolaidis

Nena

Παναγοπούλου

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

Section: Characteristics Of Included Studiesmentioning

confidence: 99%

“…The methylation of PAX1, in particular, has been extensively documented as a possible target for the detection of cervical intraepithelial neoplasia (CIN) at grade 3 or worse (CIN3 + ), with variable outcomes and endpoints [22][23][24][25][26].…”

Section: Introductionmentioning

confidence: 99%

PAX1 methylation as an auxiliary biomarker for cervical cancer screening: A meta-analysis

Nikolaidis

Nena

Παναγοπούλου

et al. 2015

Cancer Epidemiology

View full text Add to dashboard Cite

“…Epigenetic alterations, such as gene or DNA methylation, have been proposed as novel biomarkers for the cervical cancer detection. Among these altered and methylated genes, the paired boxed gene 1 (PAX1) and sex determining region Y-box 1 (SOX1) were both highlighted (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26). Numerous studies have documented the promise of PAX1 or SOX1 DNA methylation in distinguishing patients with reactive atypia or CIN3+ (cervical intraepithelial neoplasia type III or worse) lesions from normal uterine cervixes (12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23).…”

Section: Introductionmentioning

confidence: 99%

PAX1 and SOX1 methylation as an initial screening method for cervical cancer: a meta-analysis of individual studies in Asians

et al. 2016

View full text Add to dashboard Cite

Background: Epigenetic alterations of gene or DNA methylation have been highlighted as promising biomarkers for early cervical cancer screening. Herein, we evaluated the diagnostic performance of paired boxed gene 1 (PAX1) and sex determining region Y-box 1 (SOX1) methylation for cervical cancer detection.Methods: Eligible studies were retrieved by searching the electronic databases. Study quality was assessed according to the Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist. The bivariate meta-analysis model was employed to plot the summary receiver operator characteristic (SROC) curve using Stata 12.0 software. Conclusions: PAX1 or SOX1 methylation has a prospect to be an auxiliary biomarker for cervical cancer screening, and parallel testing of PAX1 methylation and HPV DNA in cervical swabs confers an improved diagnostic accuracy than single HPV DNA testing.

show abstract

“…The present study used methylation-specific PCR to demonstrate that the PAX1 gene is abnormally methylated in cervical cancer specimens, with methylation rates as high as 87.5%, which is significantly different to those in normal cervical tissues and cervical precancerous lesions (49). Furthermore, the diagnostic sensitivity was twice that of the HPV-HC2 assay (53).…”

Section: Discussionmentioning

confidence: 78%

Quantitative DNA methylation analysis of paired box gene 1 and LIM homeobox transcription factor 1 α genes in cervical cancer

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. DNA methylation is associated with tumorigenesis and may act as a potential biomarker for detecting cervical cancer. The aim of the present study was to explore the methylation status of the paired box gene 1 (PAX1) and the LIM homeobox transcription factor 1 α (LMX1A) gene in a spectrum of cervical lesions in an Eastern Chinese population. This single-center study involved 121 patients who were divided into normal cervix (NC; n=28), low-grade squamous intraepithelial lesion (LSIL; n=32), high-grade squamous intraepithelial lesion (HSIL; n=34) and cervical squamous cell carcinoma (CSCC; n=27) groups, according to biopsy results. Following extraction and modification of the DNA, quantitative assessment of the PAX1 and LMX1A genes in exfoliated cells was performed using pyrosequencing analysis. Receiver operating characteristic (ROC) curves were generated to calculate the sensitivity and specificity of each parameter and cut-off values of the percentage of methylation reference (PMR) for differentiation diagnosis. Analysis of variance was used to identify differences among groups. The PMR of the two genes was significantly higher in the HSIL and CSCC groups compared with that in the NC and LSIL groups (P<0.001). ROC curve analysis demonstrated that the sensitivity, specificity and accuracy for detection of CSCC were 0.790, 0.837 and 0.809, respectively, using PAX1; and 0.633, 0.357 and 0.893, respectively, using LMX1A. These results indicated that quantitative PAX1 methylation demonstrates potential for cervical cancer screening, while further investigation is required to determine the potential of LMX1A methylation.

show abstract

Cervical dysplasia: Assessing methylation status (Methylight) of CCNA1, DAPK1, HS3ST2, PAX1 and TFPI2 to improve diagnostic accuracy

Cited by 42 publications

References 57 publications

PAX1 methylation as an auxiliary biomarker for cervical cancer screening: A meta-analysis

PAX1 methylation as an auxiliary biomarker for cervical cancer screening: A meta-analysis

PAX1 and SOX1 methylation as an initial screening method for cervical cancer: a meta-analysis of individual studies in Asians

Quantitative DNA methylation analysis of paired box gene 1 and LIM homeobox transcription factor 1 α genes in cervical cancer

Contact Info

Product

Resources

About